Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival

Autor: Alberto J. Montero, Jingjing Liu, C. M. Diaz-Montero, Eric Jonasch, Patrick Hwu, R. E. Millikan, B. W. McIntyre, Kim Anh Do, S. Hodges, Nizar M. Tannir
Rok vydání: 2009
Předmět:
Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Time Factors
medicine.medical_treatment
Basic fibroblast growth factor
Alpha interferon
Enzyme-Linked Immunosorbent Assay
Kaplan-Meier Estimate
urologic and male genital diseases
Gastroenterology
chemistry.chemical_compound
Renal cell carcinoma
Risk Factors
Internal medicine
Carcinoma
Medicine
Humans
Carcinoma
Renal Cell
Interferon alfa
Proportional Hazards Models
Randomized Controlled Trials as Topic
Immunoassay
Chi-Square Distribution
Dose-Response Relationship
Drug
business.industry
Interleukin-12 Subunit p40
Interleukin-6
Interferon-alpha
Hematology
Original Articles
medicine.disease
Survival Analysis
Vascular endothelial growth factor A
Cytokine
Treatment Outcome
Oncology
chemistry
Immunology
Cytokines
Angiogenesis Inducing Agents
Female
Fibroblast Growth Factor 2
Interleukin-5
business
Kidney cancer
medicine.drug
Follow-Up Studies
Zdroj: Annals of oncology : official journal of the European Society for Medical Oncology. 20(10)
ISSN: 1569-8041
Popis: Background: To correlate serum cytokine and angiogenic factor (CAF) levels with overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with interferon-α (IFN-α). Patients and methods: Serum CAF levels were measured in 103 patients treated on a randomized trial with IFN-α 0.5 million units (MU) twice daily or 5 MU daily. Concentrations of 17 analytes were determined by multiplex bead immunoassays [vascular endothelial growth factor A (VEGFA) and several cytokines] or enzyme-linked immunosorbent assay (basic fibroblast growth factor). We used proportional hazards models to evaluate the effect of CAF levels and clinical factors on OS. Results: Pretreatment serum interleukin (IL) 5, IL-12 p40, VEGFA, and IL-6 levels and Memorial Sloan-Kettering Cancer Center risk grouping independently correlated with OS, with hazard ratios of 2.33, 2.00, 2.07, 1.82, and 0.39, respectively (concordance index = 0.69 for the combined model versus 0.60 for the CAF model versus 0.52 for the clinical model). Based on an index derived from these five risk factors (RFs), patients with 0–2 RF had a median OS time of 32 months versus 9 months for patients with 3–5 RF (P < 0.0001). Conclusions: Serum CAF profiling contributes to prognostic evaluation in mRCC and helps to identify a subset of patients with 20% 5-year OS.
Databáze: OpenAIRE
Externí odkaz: